Resverlogix Plays Up Importance Of New Study After Missing Phase II Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
Continuing in its quest for the holy grail of a novel HDL cholesterol drug, Resverlogix maintains that an upcoming Phase IIb trial will test a more appropriate, higher-risk population and study patients longer.
You may also be interested in...
Resverlogix’s Reprieve: ASSURE Results Suggest RVX-208 Works When Given With Crestor
While the ASSURE study failed overall, it turns out that a subset taking the HDL-raising drug candidate with the statin Crestor did benefit from treatment; Resverlogix is now planning to develop the combination.
Resverlogix’s Reprieve: ASSURE Results Suggest RVX-208 Works When Given With Crestor
While the ASSURE study failed overall, it turns out that a subset taking the HDL-raising drug candidate with the statin Crestor did benefit from treatment; Resverlogix is now planning to develop the combination.
In Anticipation Of Acquisition, Resverlogix Spins Out Epigenetics Platform
The publicly listed Canadian biotech is prepping for a potential takeout after Phase IIb for its lead candidate by spinning out its preclinical epigenetics platform into a new private company. If Resverlogix is acquired, the newco could potentially gain a royalty from the acquirer in exchange for access to IP.